The FDA approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya; Johnson & Johnson) for the treatment of adults with moderately to severely active ulcerative colitis (UC), becoming the first and only IL-23 inhibitor to offer both SC and... [6722 chars].. reed more
